Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Endocrinology|April 9, 2008
The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomasD Taïeb, L Tessonnier, F Sebag, et al.
Annales De Chirurgie|September 30, 1998
[Early therapeutic management of patients genetically predisposed to medullary thyroid cancer]A Murat, E Modigliani, B Conte-Devolx, et al.
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patientsP Niccoli-Sire, A Murat, V Rohmer, et al.
European Journal of Endocrinology|February 7, 2004
Advances in diagnostic practices affect thyroid cancer incidence in FranceL Leenhardt, M O Bernier, M H Boin-Pineau, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2010
Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs EndocrinesV Rohmer, G Vidal-Trecan, A Bourdelot, et al.
Thyroid : Official Journal of the American Thyroid Association|December 16, 1998
Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty casesN Beressi, J M Campos, J P Beressi, et al.
European Journal of Endocrinology|May 10, 2011
Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs EndocrinesP Goudet, C Bonithon-Kopp, A Murat, et al.
European Journal of Endocrinology|November 16, 2011
Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines databaseB Gatta-Cherifi, O Chabre, A Murat, et al.
The Journal of Clinical Endocrinology and Metabolism|January 17, 2015
MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs EndocrinesP Goudet, A Dalac, M Le Bras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized studyS Faivre, P Niccoli, D Castellano, et al.
Pageof 5